Combustible and non-combustible tobacco product preparations differentially regulate human peripheral blood mononuclear cell functions

Toxicology in Vitro

Volumn 27, Issue 6, 2013, Pages 1992-2004

  Arimilli, Subhashini ^a   Damratoski, Brad E ^a   Prasad, G L ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b R J REYNOLDS TOBACCO COMPANY   (United States)

Author keywords

Cytotoxicity assay; EC50; LPS; NK cells; PBMCs; Poly I:C; T cells; Tobacco product preparations (TPPs)

Indexed keywords

CIGARETTE SMOKE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; NATURAL PRODUCT; NICOTINE; PERFORIN; TOBACCO PRODUCT PREPARATION; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DOWN REGULATION; HUMAN; HUMAN CELL; LIGAND BINDING; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; PARTICULATE MATTER; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SMOKELESS TOBACCO; T LYMPHOCYTE;

CYTOTOXICITY ASSAY; EC(50); LPS; NK CELLS; PBMCS; POLY I:C; T CELLS; TOBACCO PRODUCT PREPARATIONS (TPPS);

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELLS, CULTURED; CYTOKINES; HUMANS; K562 CELLS; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; NICOTINE; PERFORIN; POLY I-C; SALIVA; SMOKE; T-LYMPHOCYTES; TOBACCO PRODUCTS;

EID: 84881099065     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2013.06.015     Document Type: Article

References (63)

1. Arimilli S., Alexander-Miller M.A., Parks G.D. A simian virus 5 (SV5) P/V mutant is less cytopathic than wild-type SV5 in human dendritic cells and is a more effective activator of dendritic cell maturation and function. J. Virol. 2006, 80:3416-3427.
2. Arimilli S., Johnson J.B., Alexander-Miller M.A., Parks G.D. TLR-4 and -6 agonists reverse apoptosis and promote maturation of simian virus 5-infected human dendritic cells through NFkB-dependent pathways. Virology 2007, 365:144-156.
3. Arimilli S., Damratoski B.E., Bombick B., Borgerding M.F., Prasad G.L. Evaluation of cytotoxicity of different tobacco product preparations. Regul. Toxicol. Pharmacol. 2012, 64:350-360.
4. Arimilli S., Damratoski B.E., Chen P., Jones B.A., Prasad G.L. Rapid isolation of leukocyte subsets from fresh and cryopreserved peripheral blood mononuclear cells in clinical research. Cryoletters 2012, 33:376-384.
5. Bancroft G.J. The role of natural killer cells in innate resistance to infection. Curr. Opin. Immunol. 1993, 5:503-510.
6. Benowitz N.L., Hukkanen J., Jacob P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handbook Exp. Pharmacol. 2009, 29-60.
7. Biron C.A. Activation and function of natural killer cell responses during viral infections. Curr. Opin. Immunol. 1997, 9:24-34.
8. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 1999, 17:189-220.
9. Borrego F., Robertson M.J., Ritz J., Pena J., Solana R. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology 1999, 97:159-165.
10. Cerwenka A., Lanier L.L. Natural killer cells, viruses and cancer. Nat. Rev. Immunol. 2001, 1:41-49.
11. Chang J.C., Distler S.G., Kaplan A.M. Tobacco smoke suppresses T cells but not antigen-presenting cells in the lung-associated lymph nodes. Toxicol. Appl. Pharmacol. 1990, 102:514-523.
12. Chen H., Cowan M.J., Hasday J.D., Vogel S.N., Medvedev A.E. Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-kappaB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J. Immunol. 2007, 179:6097-6106.
13. Chou C.C., Hee S.S.Q. Bioassay-driven analysis of chewing tobacco extracts. Environ. Toxicol. Chem. 1994, 13:1177-1186.
14. Ferson M., Edwards A., Lind A., Milton G.W., Hersey P. Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int. J. Cancer 1979, 23:603-609.
15. Fine C.I., Han C.D., Sun X., Liu Y., McCutcheon J.A. Tobacco reduces membrane HLA class I that is restored by transfection with transporter associated with antigen processing 1 cDNA. J. Immunol. 2002, 169:6012-6019.
16. Frost-Pineda K., Liang Q., Liu J., Rimmer L., Jin Y., Feng S., Kapur S., Mendes P., Roethig H., Sarkar M. Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. Nicotine Tob. Res. 2011, 13:182-193.
17. Gao H., Prasad G.L., Zacharias W. Differential cell-specific cytotoxic responses of oral cavity cells to tobacco preparations. Toxicol. In Vitro 2013, 27:282-291.
18. Goncalves R.B., Coletta R.D., Silverio K.G., Benevides L., Casati M.Z., da Silva J.S., Nociti F.H. Impact of smoking on inflammation: overview of molecular mechanisms. Inflamm. Res. 2011, 60:409-424.
19. Goud S.N., Zhang L., Kaplan A.M. Immunostimulatory potential of smokeless tobacco extract in in vitro cultures of murine lymphoid tissues. Immunopharmacology 1993, 25:95-105.
20. Hatsukami D.K., Slade J., Benowitz N.L., Giovino G.A., Gritz E.R., Leischow S., Warner K.E. Reducing tobacco harm: research challenges and issues. Nicotine Tob. Res. 2002, 4(Suppl. 2):S89-101.
21. Hogan A.E., Corrigan M.A., O'Reilly V., Gaoatswe G., O'Connell J., Doherty D.G., Lynch L., O'Shea D. Cigarette smoke alters the invariant natural killer T cell function and may inhibit anti-tumor responses. Clin. Immunol. 2011, 140:229-235.
22. Hogan A.E., Corrigan M.A., O'Reilly V., Gaoatswe G., O'Connell J., Doherty D.G., Lynch L., O'Shea D. Cigarette smoke alters the invariant natural killer T cell function and may inhibit anti-tumor responses. Clin. Immunol. 2011, 140:229-235.
23. Holt P.G., Keast D. Environmentally induced changes in immunological function: acute and chronic effects of inhalation of tobacco smoke and other atmospheric contaminants in man and experimental animals. Bacteriol. Rev. 1977, 41:205-216.
24. Hoser G., Domagala-Kulawik J., Droszcz P., Droszcz W., Kawiak J. Lymphocyte subsets differences in smokers and nonsmokers with primary lung cancer: a flow cytometry analysis of bronchoalveolar lavage fluid cells. Med. Sci. Monit. 2003, 9:BR310-BR315.
25. Johnson G.K., Poore T.K., Squier C.A., Wertz P.W., Reinhardt R.A., Vincent S.D. Prostaglandin E2 and interleukin-1 levels in smokeless tobacco-induced oral mucosal lesions. J. Periodontal Res. 1994, 29:430-438.
26. Johnson G.K., Poore T.K., Payne J.B., Organ C.C. Effect of smokeless tobacco extract on human gingival keratinocyte levels of prostaglandin E2 and interleukin-1. J. Periodontol 1996, 67:116-124.
27. Johnson M.D., Schilz J., Djordjevic M.V., Rice J.R., Shields P.G. Evaluation of in vitro assays for assessing the toxicity of cigarette smoke and smokeless tobacco. Cancer Epidemiol. Biomarkers Prevent. 2009, 18:3263-3304.
28. Johnson M.D., Schilz J., Djordjevic M.V., Rice J.R., Shields P.G. Evaluation of in vitro assays for assessing the toxicity of cigarette smoke and smokeless tobacco. Cancer Epidemiol. Biomarkers Prevent. 2009, 18:3263-3304.
29. Lambert C., McCue J., Portas M., Ouyang Y., Li J., Rosano T.G., Lazis A., Freed B.M. Acrolein in cigarette smoke inhibits T-cell responses. J. Allergy Clin. Immunol. 2005, 116:916-922.
30. Lambert C., Li J., Jonscher K., Yang T.C., Reigan P., Quintana M., Harvey J., Freed B.M. Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-kappaB1 DNA binding domain. J. Biol. Chem. 2007, 282:19666-19675.
31. Lee J., Taneja V., Vassallo R. Cigarette smoking and inflammation: cellular and molecular mechanisms. J. Dent. Res. 2012, 91:142-149.
32. Malpass G.E., Arimilli S., Prasad G.L., Howlett A.C. Complete artificial saliva alters expression of proinflammatory cytokines in human dermal fibroblasts. Toxicol. Sci. 2013.
33. Mehta H., Nazzal K., Sadikot R.T. Cigarette smoking and innate immunity. Inflamm. Res. 2008, 57:497-503.
34. Mian M.F., Lauzon N.M., Stampfli M.R., Mossman K.L., Ashkar A.A. Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J. Leukocyte Biol. 2008, 83:774-784.
35. Mian M.F., Pek E.A., Mossman K.L., Stampfli M.R., Ashkar A.A. Exposure to cigarette smoke suppresses IL-15 generation and its regulatory NK cell functions in poly I:C-augmented human PBMCs. Mol. Immunol. 2009, 46:3108-3116.
36. Mian M.F., Stampfli M.R., Mossman K.L., Ashkar A.A. Cigarette smoke attenuation of poly I:C-induced innate antiviral responses in human PBMC is mainly due to inhibition of IFN-beta production. Mol. Immunol. 2009, 46:821-829.
37. Mitchell C., Joyce A.R., Piper J.T., McKallip R.J., Fariss M.W. Role of oxidative stress and MAPK signaling in reference moist smokeless tobacco-induced HOK-16B cell death. Toxicol. Lett. 2010, 195:23-30.
38. Nadigel J., Prefontaine D., Baglole C.J., Maltais F., Bourbeau J., Eidelman D.H., Hamid Q. Cigarette smoke increases TLR4 and TLR9 expression and induces cytokine production from CD8(+) T cells in chronic obstructive pulmonary disease. Respir. Res. 2011, 12:149.
39. Nordskog B.K., Fields W.R., Hellmann G.M. Kinetic analysis of cytokine response to cigarette smoke condensate by human endothelial and monocytic cells. Toxicology 2005, 212:87-97.
40. Ouyang Y., Virasch N., Hao P., Aubrey M.T., Mukerjee N., Bierer B.E., Freed B.M. Suppression of human IL-1beta, IL-2, IFN-gamma, and TNF-alpha production by cigarette smoke extracts. J. Allergy Clin. Immunol. 2000, 106:280-287.
41. Parsanejad R., Fields W.R., Steichen T.J., Bombick B.R., Doolittle D.J. Distinct regulatory profiles of interleukins and chemokines in response to cigarette smoke condensate in normal human bronchial epithelial (NHBE) cells. J. Interferon Cytokine Res. 2008, 28:703-712.
42. Petro T.M. Modulation of IL-12 p35 and p40 promoter activity by smokeless tobacco extract is associated with an effect upon activation of NF-kappaB but not IRF transcription factors. Int. Immunopharmacol. 2003, 3:735-745.
43. Petro T.M., Zhang S. The effect of smokeless tobacco extract on murine T cell cytokine production. Immunopharmacology 1997, 36:17-26.
44. Petro T.M., Schwartzbach S.D., Zhang S. Smokeless tobacco and nicotine bring about excessive cytokine responses of murine memory T-cells. Int. J. Immunopharmacol. 1999, 21:103-114.
45. Phipps J.C., Aronoff D.M., Curtis J.L., Goel D., O'Brien E., Mancuso P. Cigarette smoke exposure impairs pulmonary bacterial clearance and alveolar macrophage complement-mediated phagocytosis of Streptococcus pneumoniae. Infect. Immun. 2010, 78:1214-1220.
46. Reimer T., Brcic M., Schweizer M., Jungi T.W. Poly(I:C) and LPS induce distinct IRF3 and NF-kappaB signaling during type-I IFN and TNF responses in human macrophages. J. Leukocyte Biol. 2008, 83:1249-1257.
47. Rickert W.S., Joza P.J., Trivedi A.H., Momin R.A., Wagstaff W.G., Lauterbach J.H. Chemical and toxicological characterization of commercial smokeless tobacco products available on the Canadian market. Regul. Toxicol. Pharmacol. 2009, 53:121-133.
48. Roos-Engstrand E., Pourazar J., Behndig A.F., Blomberg A., Bucht A. Cytotoxic T cells expressing the co-stimulatory receptor NKG2 D are increased in cigarette smoking and COPD. Respir. Res. 2010, 11:128.
49. Rufino R., Madi K., Souza H.S., Costa C.H., Saito E.H., Silva J.R. Quantitative assessment of elastic fibers in chronic obstructive pulmonary disease. J. Bras. Pneumol. 2007, 33:502-509.
50. Rumora L., Milevoj L., Popovic-Grle S., Barisic K., Cepelak I., Grubisic T.Z. Levels changes of blood leukocytes and intracellular signalling pathways in COPD patients with respect to smoking attitude. Clin. Biochem. 2008, 41:387-394.
51. Schoenborn J.R., Wilson C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 2007, 96:41-101.
52. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukocyte Biol. 2004, 75:163-189.
53. Smyth M.J., Thia K.Y., Cretney E., Kelly J.M., Snook M.B., Forbes C.A., Scalzo A.A. Perforin is a major contributor to NK cell control of tumor metastasis. J. Immunol. 1999, 162:6658-6662.
54. Sopori M. Effects of cigarette smoke on the immune system. Nat. Rev. Immunol. 2002, 2:372-377.
55. Sopori M.L., Kozak W. Immunomodulatory effects of cigarette smoke. J. Neuroimmunol. 1998, 83:148-156.
56. Tsuyusaki J., Kuroda F., Kasuya Y., Ishizaki S., Yamauchi K., Sugimoto H., Kono T., Iwamura C., Nakayama T., Tatsumi K. Cigarette smoke-induced pulmonary inflammation is attenuated in CD69-deficient mice. J. Receptor Signal Trans. Res. 2011, 31:434-439.
57. US Department of Health and Human Services, 2010. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. In: Affairs, H. (Eds.), A Report of the Surgeon General, US Department of Health and Human Services, C.f.D.C.a.P., National Center for Chronic Disease Prevention and Health Promotion, O.o.S.a.
58. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996, 274:787-789.
59. Wu J., Joza P., Sharifi M., Rickert W.S., Lauterbach J.H. Quantitative method for the analysis of tobacco-specific nitrosamines in cigarette tobacco and mainstream cigarette smoke by use of isotope dilution liquid chromatography tandem mass spectrometry. Anal. Chem. 2008, 80:1341-1345.
60. Yao H., Rahman I. Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol. Appl. Pharmacol. 2011, 254:72-85.
61. Yoneda K., Osaki T., Yamamoto T., Ueta E. Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes. Clin. Exp. Immunol. 1993, 93:229-236.
62. Zeller M., Hatsukami D., Strategic Dialogue on Tobacco Harm Reduction Group The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tobacco Control 2009, 18:324-332.
63. Ziegler S.F., Ramsdell F., Alderson M.R. The activation antigen CD69. Stem Cells 1994, 12:456-465.